Related Experiment Video

Updated: May 4, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K

Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC

Stéphane Champiat1, Ecaterina Ileana, Giuseppe Giaccone

  • 1*SITEP (Service d'Innovations Therapeutiques Precoces), Department of Medicine, Gustave Roussy, †Institut Gustave Roussy, University Paris Sud, Villejuif, France; ‡Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia; §Thoracic Multidisciplinary Committee, Gustave Roussy, University Paris Sud, Villejuif, France; and ‖Department of Medical Oncology, University of Athens School of Medicine, Athens, Greece.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|January 15, 2014
PubMed

Insights

Metastatic non-small-cell lung cancer (NSCLC) remains challenging. Combining immune-checkpoint inhibitors with conventional therapies may improve treatment efficacy by enhancing anti-tumor immunity.

Area of Science:

  • Oncology
  • Immunology
  • Medical Research

Background:

  • Metastatic non-small-cell lung cancer (NSCLC) currently lacks a cure despite available treatments.
  • Targeted therapies show promise but often lead to acquired resistance and disease progression.
  • Immune-checkpoint blockade (ICB) has emerged as a promising strategy for metastatic NSCLC, demonstrating durable responses in early trials.

Purpose of the Study:

  • To review the efficacy of immune-checkpoint inhibitors in NSCLC clinical trials.
  • To explore the immunomodulatory effects of conventional and targeted therapies.
  • To provide a rationale and identify challenges for combining ICB with existing treatments in NSCLC.

Main Methods:

  • Literature review of clinical trials involving immune-checkpoint inhibitors in NSCLC.
  • Analysis of studies on the immune-modulating properties of conventional and targeted cancer therapies.
  • Synthesis of data to support combination strategies.

Main Results:

  • ICB has shown significant potential for durable responses in metastatic NSCLC.
  • Conventional and targeted therapies can modulate the immune system, potentially synergizing with ICB.
  • Combination therapies may induce tumor lysis and sustained immune-mediated control.

Conclusions:

  • Immune-checkpoint inhibitors are likely to be integral to future NSCLC treatment strategies.
  • Combining ICB with conventional or targeted therapies holds promise for improved efficacy.
  • Careful consideration of potential synergistic activities and toxicity profiles is crucial for successful combination approaches.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K